Consistent with this possibility, we found that pimozide showed equal potency towards CML cells harboring wildtype BCR/ABL and BCR/ABL containing a T315I mutation which renders it resistant to all currently approved kinase inhibitors [12]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.